Literature DB >> 3032031

Transpulmonary angiotensin II formation in patients with chronic stable cor pulmonale.

J B Neilly, C J Clark, A Tweddel, A P Rae, D M Hughes, I Hutton, J J Morton, R D Stevenson.   

Abstract

The activity of the renin-angiotensin (RA) system and the ability of the lungs to generate angiotensin II (AII) were studied in 11 patients with stable cor pulmonale and respiratory failure caused by chronic obstructive bronchitis and emphysema. Angiotensin I concentrations (18.7 +/- 8.3 pmol/L) were normal, and transpulmonary AII formation rates (TRAIIFR) (14.2 +/- 18.1 pmol/min) were not significantly different from those recorded in nonedematous cardiac subjects (19.9 +/- 20.1 pmol/min), matched for sex, age, and diuretic therapy. The main determinant of TPAIIFR was the mixed venous AI concentration. Administration of oxygen for 30 min led to a small increase in TPAIIFR in the majority of patients. This increase could not be accounted for by changes in mixed venous AI. There was no correlation between serum angiotensin-converting enzyme levels and either the TPAIIFR or the systemic arterial AII concentrations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032031     DOI: 10.1164/arrd.1987.135.4.891

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Effects of captopril in patients with chronic obstructive pulmonary disease and secondary pulmonary hypertension.

Authors:  D Patakas; D Georgopoulos; H Rodini; P Christaki
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

3.  Activity of the renin-angiotensin system in acute severe asthma and the effect of angiotensin II on lung function.

Authors:  E A Millar; R M Angus; G Hulks; J J Morton; J M Connell; N C Thomson
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.